Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Seyltx, Inc.

Seyltx Expands GluN2B Antagonist Pipeline with Clinical-Stage and Small-Molecule Candidates for Chronic Cough
From Seyltx, Inc.
Via Business Wire
Seyltx Announces Positive Non-Human Primate (NHP) and Additional In Vivo Data for its Centrally Acting Inhibitor of GluN2B in Chronic Cough, Paving the Way for Optimized Later-Stage Phase 2 Trials
From Seyltx, Inc.
Via Business Wire
Seyltx Announces Positive Pre-Clinical Dose-Ranging Data with Its Selective Oral Small-Molecule Inhibitor of GluN2B Illustrating Near-Complete Suppression of Refractory Chronic Cough within the Therapeutic Index
From Seyltx, Inc.
Via GlobeNewswire
Seyltx Announces Results of Electronic Health Record Analysis to Determine the Prevalence of Refractory Chronic Cough
From Seyltx, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.